BLOG

Wednesday, October 3, 2018

India biz may stabilise in FY19, but govt price caps a concern: Sun Pharma

The company's India business revenues stood at Rs 80.29 billion in 2017-18, a growth of 4 per cent over 2016-17

from Companies https://ift.tt/2RhbfUB
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...